{"id":"https://openalex.org/W2562559362","doi":"https://doi.org/10.1182/blood.v110.11.387.387","title":"A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.","display_name":"A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.","publication_year":2007,"publication_date":"2007-11-16","ids":{"openalex":"https://openalex.org/W2562559362","doi":"https://doi.org/10.1182/blood.v110.11.387.387","mag":"2562559362"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v110.11.387.387","doi":"https://doi.org/10.1182/blood.v110.11.387.387","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.387.387","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054354872","display_name":"Elliot M. Epner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elliot M. Epner","raw_affiliation_strings":["Center for Hematologic Malignancies, Dept of Medicine, Oregon Health and Science University, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Hematologic Malignancies, Dept of Medicine, Oregon Health and Science University, Portland, OR, USA","institution_ids":["https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091192260","display_name":"Joseph M. Unger","orcid":"https://orcid.org/0000-0002-5191-0317","observed_orcids":["https://orcid.org/0000-0002-5191-0317"]},"institutions":[{"id":"https://openalex.org/I4210165553","display_name":"SWOG Cancer Research Network","ror":"https://ror.org/05n6zrm60","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210165553"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Unger","raw_affiliation_strings":["SWOG Lymphoma Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SWOG Lymphoma Group","institution_ids":["https://openalex.org/I4210165553"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102767715","display_name":"Thomas P. Miller","orcid":"https://orcid.org/0000-0002-7100-2682","observed_orcids":["https://orcid.org/0000-0002-7100-2682"]},"institutions":[{"id":"https://openalex.org/I4210165553","display_name":"SWOG Cancer Research Network","ror":"https://ror.org/05n6zrm60","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210165553"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Miller","raw_affiliation_strings":["SWOG Lymphoma Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SWOG Lymphoma Group","institution_ids":["https://openalex.org/I4210165553"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080313708","display_name":"Lisa Rimzsa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165553","display_name":"SWOG Cancer Research Network","ror":"https://ror.org/05n6zrm60","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210165553"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Rimzsa","raw_affiliation_strings":["SWOG Lymphoma Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SWOG Lymphoma Group","institution_ids":["https://openalex.org/I4210165553"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113605893","display_name":"Catherine M. Spier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165553","display_name":"SWOG Cancer Research Network","ror":"https://ror.org/05n6zrm60","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210165553"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Spier","raw_affiliation_strings":["SWOG Lymphoma Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SWOG Lymphoma Group","institution_ids":["https://openalex.org/I4210165553"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041539801","display_name":"Michael Leo LeBlanc","orcid":"https://orcid.org/0000-0001-7192-2860","observed_orcids":["https://orcid.org/0000-0001-7192-2860"]},"institutions":[{"id":"https://openalex.org/I4210165553","display_name":"SWOG Cancer Research Network","ror":"https://ror.org/05n6zrm60","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210165553"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Leblanc","raw_affiliation_strings":["SWOG Lymphoma Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SWOG Lymphoma Group","institution_ids":["https://openalex.org/I4210165553"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111441938","display_name":"Richard I. Fisher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165553","display_name":"SWOG Cancer Research Network","ror":"https://ror.org/05n6zrm60","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210165553"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Fisher","raw_affiliation_strings":["SWOG Lymphoma Group"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SWOG Lymphoma Group","institution_ids":["https://openalex.org/I4210165553"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":6.4402,"has_fulltext":false,"cited_by_count":60,"citation_normalized_percentile":{"value":0.96932051,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"110","issue":"11","first_page":"387","last_page":"387"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9779999852180481},{"id":"https://openalex.org/keywords/hyper-cvad","display_name":"hyper-CVAD","score":0.921999990940094},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9729999899864197},{"id":"https://openalex.org/keywords/newly-diagnosed-lymphoma","display_name":"newly diagnosed lymphoma","score":0.8579999804496765},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8479999899864197},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8669999837875366},{"id":"https://openalex.org/keywords/complete-response-rate","display_name":"complete response rate","score":0.8130000233650208},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.7599999904632568},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.550000011920929},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.4320000112056732},{"id":"https://openalex.org/keywords/southwest-oncology-group","display_name":"Southwest Oncology Group","score":0.6389999985694885},{"id":"https://openalex.org/keywords/measurable-disease","display_name":"measurable disease","score":0.3269999921321869},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.375}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8896068334579468},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.7432011365890503},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6694065928459167},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6640243530273438},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.6450889110565186},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.49390798807144165},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.48237910866737366},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.46898016333580017},{"id":"https://openalex.org/C2778476033","wikidata":"https://www.wikidata.org/wiki/Q1667625","display_name":"International Prognostic Index","level":4,"score":0.45652997493743896},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.45306476950645447},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4441972076892853},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.4425247311592102},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.2706601619720459},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.25731194019317627}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v110.11.387.387","doi":"https://doi.org/10.1182/blood.v110.11.387.387","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.387.387","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8100000023841858}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2135404678","https://openalex.org/W2563731036","https://openalex.org/W2571599701","https://openalex.org/W1969049855","https://openalex.org/W2045713409","https://openalex.org/W2164427041","https://openalex.org/W2117968434","https://openalex.org/W2103294438","https://openalex.org/W2049159227","https://openalex.org/W2123502344"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND:":[1],"A":[2],"Phase":[3],"II":[4,97],"Study":[5],"multinstitutional":[6],"study":[7,56,92],"by":[8,57],"the":[9,13,23,63,131,285,377],"lymphoma":[10,36],"group":[11,46],"within":[12],"Southwest":[14],"Oncology":[15],"Group":[16],"(SWOG":[17],"0213)":[18],"was":[19,41,93,163,175,223,297,347],"performed":[20],"to":[21,169,196,376],"determine":[22],"1":[24,267],"year":[25,81,268,294,301,308,316,368],"progression":[26,302,369],"free":[27,83,303,370],"survival":[28,84,244,264,296,304,326,336,371],"of":[29,47,86,99,127,179,224,284,372,390],"patients":[30,51,138,159,182,189,199,205,213,233,288],"with":[31,116,142,365],"newly":[32,48],"diagnosed":[33,49,136],"mantle":[34],"cell":[35],"(MCL).":[37],"Previously,":[38],"this":[39,382],"regimen":[40,358,383],"utilized":[42],"in":[43,52,363],"a":[44,53,70,74,79,94,125,366,387],"similar":[45,375],"MCL":[50,137,364],"single":[54],"institution":[55],"Romaguera":[58],"et":[59],"al":[60],"(JCO200523:7013)":[61],"at":[62,246,254,266,275],"MD":[64,132,379],"Anderson":[65,133,380],"Cancer":[66],"Center.":[67],"They":[68],"reported":[69,176,362,378],"97%":[71],"response":[72,221,345],"rate,":[73,77],"87%":[75,178],"CR":[76],"and":[78,106,146,193,211,253,274,299,386],"3":[80,188],"failure":[82],"rate":[85,222,346],"73%.":[87],"PATIENTS":[88],"AND":[89],"METHODS:":[90],"This":[91],"prospective":[95],"phase":[96],"trial":[98],"rituximab":[100,117,357],"plus":[101,118],"fractionated":[102],"cyclophosphamide,":[103],"vincristine,":[104],"doxorubicin,":[105],"dexamethasone":[107],"(hyperCVAD;":[108],"considered":[109],"one":[110,122,164,300,367],"cycle)":[111,123],"alternating":[112],"every":[113],"21":[114],"days":[115],"high-dose":[119],"methotrexate-cytarabine":[120],"(considered":[121],"for":[124,177,186,218],"total":[126],"eight":[128],"cycles":[129],"per":[130],"protocol.":[134],"Newly":[135],"under":[139],"age":[140],"70":[141],"adequate":[143],"organ":[144],"function":[145],"measurable":[147],"disease":[148],"were":[149,153,160],"eligible.":[150],"All":[151],"cases":[152],"histologically":[154],"confirmed.":[155],"RESULTS:":[156],"49":[157,286],"eligible":[158,287],"enrolled.":[161],"There":[162],"probable":[165],"treatment-related":[166],"death":[167],"due":[168],"colitis.":[170],"Grade":[171],"4":[172],"hematologic":[173],"toxicity":[174],"patients.":[180],"40":[181],"have":[183,289],"been":[184],"evaluated":[185],"response.":[187],"had":[190,201,207,215],"inadequate":[191],"assessment":[192],"are":[194],"assumed":[195],"be":[197],"non-responders.16":[198],"(40%)":[200],"complete":[202,209],"responses,":[203,210],"7":[204],"(18%)":[206],"unconfirmed":[208],"12":[212],"(30%)":[214],"partial":[216],"responses":[217],"an":[219],"overall":[220,263,295,335,344],"88%":[225,348],"(35/40;":[226,349],"95%":[227,350],"CI,":[228,351],"73%\u201396%).":[229,352],"Median":[230],"follow-up":[231],"among":[232],"still":[234],"alive":[235],"is":[236,248,257,269,278,305,310,318,328,338,359,384,394],"1.6":[237],"years":[238,256,277],"(range:":[239],"0.3\u20134.1":[240],"years).":[241],"The":[242,262,323,333,343,354],"progression-free":[243,325],"estimate":[245,265,327,337],"1-year":[247,324,334],"89%":[249,329],"(95%":[250,259,271,280,312,320,330,340],"CI:":[251,260,272,281,313,321,331,341],"80%\u201398%)":[252],"2":[255,276],"64%":[258],"46%\u201382%).":[261,314],"91%":[270,298,339],"82%\u201399%)":[273],"76%":[279,319],"60%\u201391%).":[282,322],"13":[283],"progressed":[290],"or":[291],"died.":[292],"One":[293],"89%.":[306,373],"Two":[307,315],"PFS":[309],"63%":[311],"OS":[317],"80%\u201398%).":[332],"82%\u201399%).":[342],"CONCLUSIONS:":[353],"hyperCVAD":[355],"+":[356],"active":[360],"as":[361],"However,":[374],"experience,":[381],"toxic":[385],"continuous":[388],"pattern":[389],"relapse":[391],"over":[392],"time":[393],"observed.":[395]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":9}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2025-10-10T00:00:00"}